Form D · Pharmaceuticals
Terpenoid Therapeutics, Inc.
Coralville, IA · CIK 0001480768
Offering snapshot reported Nov 29, 2017 · SEC filing
- Reported sold
- $536K Offering amount: $536K
- Investors reported
- 5 Form D · investor count
- Minimum accepted
- $50K Reported outside-investor minimum
- First sale
- Mar 3, 2016 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 29, 2017 | Initial | $535,871 | No comparison | 5 | SEC filing |
| Nov 29, 2017 | Initial | $802,500 | No comparison | 10 | SEC filing |
| Jan 14, 2010 | Initial | $950,000 | No comparison | 14 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-299751
Source: Form D, filed Nov 29, 2017. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Steven Collins | Director, Executive |
| Mark J Drish | Director |
| Raymond J Hohl | Director, Executive |
| Robert W. Karr | Director, Executive |
| Jeffrey D. Neighbors | Executive |
| Curt Nelson | Director |
| David F Weimer | Director |
| David Wiemer | Director, Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
2500 Crosspark Road Suite E156 W
Coralville, IA, 52241
Coralville, IA, 52241